## Aytu BioPharma Reports First Quarter 2022 Financial Results

Quarterly net revenue increased 62% to \$21.9 million

Ended quarter with approximately \$40.6 million in cash, cash equivalents and restricted cash

Fully integrated and expanding RxConnect patient support program and salesforce drove growth across prescription portfolio

Planned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22

Initiation of Healight randomized, sham-controlled study by year-end 2021

Management to host live conference call and webcast today at 4:30 p.m. ET

**ENGLEWOOD, CO / November 15, 2021** / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for its fiscal first quarter 2022 ended September 30, 2021.

"We posted a very strong quarter with net revenues of \$21.9 million and two of our commercial products, Poly-Vi-Flor and Adzenys XR-ODT, hitting all-time highs in prescription performance. We have begun delivering on our projection that fiscal 2022 will be a year of substantial progress, as we continued to realize the economic benefits of our merger synergy plan following the Neos Therapeutics acquisition, organically grew our commercial prescription and consumer health product revenues and advanced our late-stage development pipeline toward key milestones," commented Josh Disbrow, chief executive officer of Aytu BioPharma. "Regarding AR101, we expect to begin our pivotal study in early 2022, are seeking Orphan Drug Designation from the FDA and EMA, and have already begun collaborating with our newly formed scientific advisory board. We are also nearing the start of our sham-controlled study of Healight at a leading academic center in Barcelona, Spain and expect to have data in the first half of calendar year 2022. With the establishment of key fundamentals across our business, we are excited about the future as we continue building a leading specialty pharmaceutical company."

#### **First Quarter Fiscal 2022 Financial Results:**

- Net revenue for the first quarter of fiscal year 2022 was \$21.9 million, compared to \$13.5 million in the same quarter in fiscal year 2021, a 62% increase year-over-year.
  - Net revenue from the consumer health division in the first quarter of fiscal year
     2022 was \$8.0 million, compared to \$7.8 million in the same quarter last year, a

- growth of over 3% year-over-year.
- Net revenue from the prescription division in the first quarter of fiscal 2022 was \$13.9 million, compared to \$5.8 million in the same quarter last year, a growth of over 140% year-over-year.
- Gross profit increased to \$12.5 million in the first quarter of fiscal 2022, the highest quarterly gross profit posted by the company, compared to \$9.5 million in the same quarter in fiscal year 2021.
- Net loss for the first quarter of fiscal year 2022 was \$27.9 million, or \$1.09 per share.
  - Net loss was impacted by impairment expense of \$19.5 million due to the write-off of goodwill related to the company's Aytu BioPharma segment.
- Cash, cash equivalents and restricted cash totaled \$40.6 million as of September 30, 2021.

## **Recent Corporate Highlights:**

- Significant progress made on the Aytu-Neos integration and realization of synergies and operational improvements: The first quarter of fiscal year 2022 marked the second full quarter as a newly merged company and the first full quarter operating with an integrated sales force of 50 sales specialists and newly branded RxConnect patient access program. During the quarter, the company experienced significant growth of RxConnect, with Neos legacy products and Aytu legacy products now integrated into the program. The company also continued to progress the technology transfer of heritage Neos brands out of its Grand Prairie, Texas manufacturing facility to a global contract manufacturer and is on track to complete this transition in the first half of calendar year 2023. The company expects to improve gross profit margin, reduce operating expenses and significantly reduce cash exposure from inventory builds as a result of this transition.
- ADHD prescription products grew 12% during the quarter: During the first quarter of fiscal year 2022, Aytu experienced 12% growth in prescriptions for ADHD brands Adzenys XR-ODT and Cotempla XR-ODT compared to the same quarter last year. Adzenys XR-ODT prescriptions grew 15% during the three-months ended September 30, 2021 compared to the same period last year. Demand for these products continues to grow, exemplified by all-time high weekly prescription levels for Adzenys XR-ODT during the week ending October 15<sup>th</sup>, and Cotempla XR-ODT weekly prescriptions also approaching all-time high levels.
- Strong pediatric prescription products performance: During the first quarter of fiscal year 2022, the company reported 8% growth of prescription multi-vitamins compared to the same period last year, reaching all-time highs in prescriptions for Poly-Vi-Flor chewable tablets. In addition, Karbinal ER, the company's prescription antihistamine, grew 46% during the first quarter of fiscal year 2022 compared to the same period last year.

#### **Recent Pipeline Highlights**

- Formed Scientific Advisory Board (SAB) with scientific and clinical experts to support the development of AR101 for VEDS: In September 2021, Aytu announced the formation of a new SAB, consisting of leading experts in rare, genetic, pediatric diseases and chaired by Dr. Hal Dietz, M.D., Professor of Genetic Medicine at the Johns Hopkins University School of Medicine, who has conducted the groundbreaking research to date supporting AR101 in VEDS. Other initial members of the SAB include Xavier Jeunemaitre, M.D., Ph.D., Professor of Genetics at University Paris Descartes; Peter Byers, M.D., Professor of Medicine, Pathology and Medical Genetics at the University of Washington; Bart Loeys M.D., Ph.D., Professor of Medical Genetics and Cardiogenomics at the Center for Medical Genetics of the Antwerp University Hospital in Belgium and in the Department of Human Genetics in the Radboud University Medical Center in Nijmegen, The Netherlands; and Shaine A. Morris, M.D., M.P.H., Medical Director of the Cardiovascular Genetics Program at Texas Children's Hospital and Associate Professor at Baylor College of Medicine.
- Pivotal study-enabling work and site initiations ongoing for AR101 clinical trial: Investigational New Drug (IND) submission preparations and study site qualifications are underway for the planned pivotal clinical trial of AR101, a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. There are currently no U.S. Food and Drug Administration (FDA)-approved treatments for VEDS.
- Announced the publication of Healight™ endotracheal catheter technology data that continue to build upon the body of scientific evidence supporting the potential of this UVA platform technology: In July 2021, the company announced publication of data which demonstrated that ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with coronavirus. These data provide additional proof of concept and proposed mechanism of action of the Healight technology, supporting the potential use in respiratory infections.

#### **Key Anticipated Upcoming Milestones and Events:**

- Aytu is pursuing Orphan Drug Designation (ODD) from the FDA and the European Medicines Agency (EMA) for AR101, with the goal of receiving ODD in the first half of calendar year 2022.
- The company plans to launch a single pivotal trial, the PREVEnt Trial, of AR101 in patients with VEDS in the first half of calendar 2022. The planned patient enrollment for this randomized, placebo-controlled study is 260, randomized 1:1. The primary endpoint of this trial is reduction in fatal or non-fatal arterial events, such as ruptures, dissections, and pseudo-aneurisms. The company expects to fully enroll the study by

- early calendar year 2023.
- The company is on track to initiate a study evaluating Healight for the treatment of patients with SARS-CoV-2 in 2021. This randomized, sham-controlled study will evaluate the safety and treatment effects of Healight in patients with SARS-CoV-2 that have been newly intubated and on mechanical ventilation. This study will be conducted at a leading academic hospital in Barcelona, Spain and is expected to enroll 40 patients. The primary endpoint of this study is change in viral load in endotracheal tube aspirates between day zero and the last day of treatment between treated and untreated subjects. The company expects to report top-line data in the first half of 2022.

#### **Conference Call Details**

The company will host a live conference call at 4:30 p.m. ET today. The conference call can be accessed by dialing either 877-545-0320 (toll-free) or 973-528-0002 (international), participant access code 664921. The webcast will be accessible live and archived at the following link: https://www.webcaster4.com/Webcast/Page/2142/43552 and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days. A replay of the call will be available for fourteen days. Access the replay by calling 877-481-4010 (toll-free) or 919-882-2331 (international), using the replay access code 43552.

## About Aytu BioPharma, Inc.

Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING). The company also markets ZolpiMist, a short-term treatment for insomnia characterized by difficulties with sleep initiation (see Full Prescribing Information, including Boxed WARNING). The company's other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company's evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. Aytu is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome (VEDS), a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. VEDS is a devastating condition for which there are no currently approved treatments. AR101 is an

orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways. AR101 has been studied in more than 3,300 patients across a range of solid and hematological tumor types, and we are now planning a randomized, controlled, pivotal clinical study with AR101 in VEDS. To learn more, please visit aytubio.com.

#### **Forward-Looking Statements**

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as 'may,' 'will,' 'should,' 'forecast,' 'could,' 'expect,' 'suggest,' 'believe,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'plan,' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the company's plans relating to the clinical development and commercialization of AR101, the company's overall financial and operational performance, the anticipated start dates, durations and completion dates, as well as the potential future results of the company's ongoing and future clinical trials, the anticipated designs of the company's future clinical trials, the company's ability to transfer its technology and the anticipated benefits of that transfer, and the anticipated future regulatory submissions, potential adverse changes to our financial position or the company's business, the results of operations, strategy and plans, changes in capital markets and the ability of the company to finance operations in the manner expected, risks relating to gaining market acceptance of our products, risks related to the ongoing COVID-19 pandemic and its impact on our operations, our ability to effectively integrate operations and manage integration costs following our acquisitions, our partners performing their required activities, our anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaboration. We also refer you to (i) the risks described in 'Risk Factors' in Part I, Item 1A of Aytu's most recent Annual Report on Form 10-K and in the other reports and documents it files with the Securities and Exchange Commission and (ii) the Risk Factors set forth in Aytu's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC.

#### **Financial Tables**

AYTU BIOPHARMA, INC. AND SUBSIDIARIES Consolidated Statements of Operations

# (In thousands, except share and per-share) (Unaudited)

	Three Mo	Three Months Ended		
	Septe	mber	er 30,	
	2021		2020	
Product revenue, net	\$ 21,897	\$	13,520	
Cost of sales	9,441		4,063	
Gross profit	12,456		9,457	
Operating expenses				
Research and development	2,096		183	
Selling and marketing	9,297		5,826	
General and administrative	8,216		5,420	
Impairment of goodwill	19,453		-	
Amortization of intangible assets	1,093		1,585	
Total operating expenses	40,155		13,014	
Loss from operations	(27,699	)	(3,557)	
Other (expense) income				
Other (expense), net	(40	•	(751)	
Gain / (Loss) from contingent consideration	(219	)	2	
Total other (expense) income	(259	)	(749)	
Loss before income tax	(27,958	)	(4,306)	
Income tax expense (benefit)	(107	)		
Net loss	\$ (27,851	) \$.	(4,306)	
Weighted average number of common shares outstanding	25,597,319		12,158,594	
Basic and diluted net loss per common share	\$ (1.09	) \$	(0.35)	

## AYTU BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per-share)

Same of Same In Comment Assistation Basis In Comment In Com		(Unaudited) September 30,		June 30,	
Carb and cash equivalents         \$ 40,008         \$ 40,008         \$ 20,22         252				2020	
Restricted cash         252         252           Accounts receivable, est         21.66         28.16           Inventory, net         61.634         16.339           Prepaid expenses         9.434         10.83           Other current assets         89.038         10.28           Total current assets         89.038         10.28           Total current assets         3.026         3.50           Freyerly and equipment, net         4.666         5.10           Operating lease righthe-fuses asset         83.08         8.54           Codwill         46.439         6.54           Codwill         46.439         6.54           Codwill         46.549         6.54           Codwill assets         8.08         8.08           Labilities         1.80         1.80           Current stabilities         9.93         9.92           Current stabilities         9.93         9.93           Accrued Compensation         9.93         9.52           Accrued Compensation         9.93         9.93           Accrued Compensation         9.93         9.93           Accrued Compensation         9.93         9.93           Current portion of operating					
Inventation, and inventation (all parts)         1,51,64         5,13,76           Inventation, and (all parts)         1,51,64         3,70           Other current seasts         1,109         1,000           Other current seasts         4,666         5,13,24           Property and equipment, net         4,666         3,203         1,50,33           Other current seasts         3,305         3,503         1,50,33           Interrigible seasts, net         3,305         3,503         1,50,30           Cool-build         4,666         4,606         4,606           Other long-term seases         4,606         4,606         4,606           Otal long-term seases         3,306         3,508         4,606           Total long-term seases         3,306         3,508         4,606           Total long-term seases         8,308         4,606         4,606           Total long-term seases         8,308         4,606         4,606           Total long-term seases         8,308         8,008         4,606           Total long-term seases         8,308         8,008         4,606           Total long-term seases         8,308         8,008         4,502           Coccurrent long-term seases         <	Cash and cash equivalents	\$	40,308	\$ 49,649	
Prepaid experts   16.114   16.134   1	Restricted cash		252	252	
Properties desponses         9,145         9,700           Other current assets         80,03         10,20           Topic current assets         80,03         10,20           Operating leaser infe-of-use asset         4,60         5,10           Operating leaser infe-of-use asset         83,05         3,50           Infrançile assets, net         83,05         3,50           Ober Imperterm assets         46,30         6,50           Cher Imperterm assets         13,60         6,50           Other Long-term assets         13,60         1,60           Total Ing-iterm assets         1,00         1,20           Total Ing-iterm assets         1,00         1,20           Labilities         1,00         1,20           Current Isolities         1,00         1,20           Current Isolities         1,00	Accounts receivable, net		21,626	28,176	
Other current assets         1.156         1.038           Total current assets         80.03         10.524           Property and equipment, net         4.666         5.10           Operating lease righte-fue asset         3.265         3.266           Coolwill         46.09         3.265         3.676           Coolwill         46.09         3.00         4.676           Other long-term assets         13.061         1.00         4.676           Otal Journal assets         2.276         5.265         4.676           Total saysets         5.93.38         1.025         5.265           View Internal assets         5.93.38         1.025         5.025           Total saysets         5.93.38         1.025         5.036         5.	Inventory, net		16,314	16,339	
Property and equipment, net	Prepaid expenses		9,343	9,780	
Properly and equipment, net   4.66	Other current assets		1,195	1,038	
International passer injint-ofesa assert in foreign sears in fire foreign sears in fire foreign sears in family be asset, not in family be asset	Total current assets		89,038	105,234	
Manipuls assets, net	Property and equipment, net		4,666	5,140	
Odwill         46,349         5,802           Othe Indystem assets         46,56         4,605           Total long-tem assets         2,027,209         5,026,006           Itabilities         5         2,027,209         5,026,006           Accounts payable and other         5,03,381         5,129,205         5,029,207         5,029,207           Accrued Longensation         4,762         5,338         5,129,205         5,029,207	Operating lease right-of-use asset		3,826	3,563	
Other long-term assets         465         476.5           Total parkers         138.69         10.00           Total parkers         \$ 227.72         2 50.566           Learn transporting to the control parkers           Learn transporting to the control parkers         \$ 3.00         \$ 1.00           Accrued liabilities         \$ 5.30         \$ 1.02           Accrued compensation         4 762         \$ 1.03           Non-term line of credit         4 762         \$ 7.03           Current portion of dekt         1,00         \$ 4.00         \$ 1.00           Current portion of operating lease liabilities         1,00         \$ 1.00         \$ 1.00           Current portion of offkeed payment arrangements         2,12         3.13         4.00           Current portion of CVR liabilities         9,997         10,948         4.00           Current portion of contingent consideration         2,13         4.00	Intangible assets, net		83,385	85,464	
Total long-term assets         138,601         160,404           Total sasets         5         27,70         5         25,005           Labilities         Current liabilities         \$         9,383         \$         19,255           Accrued compensation         \$         9,383         \$         19,255           Accrued compensation         \$         9,383         \$         19,255           Current portion of deed         4,702         \$         9,383         \$         1,025           Current portion of deed         4,702         \$         9,383         \$         1,025           Current portion of deed till esse liabilities         16,508         \$         1,608	Goodwill		46,349	65,802	
Data assets         5         27,729         \$         26,600           Liabilities         Current liabilities         S         2,833         \$         19,255           Accrued tompersation         5         54,380         51,295           Accrued compensation         4,762         5,939           Short-term line of credit         4,650         1,658         1,668           Current portion of debt         1,658         1,668         1,668           Current portion of prescripting lease liabilities         1,108         4,940           Current portion of fixed payment arrangements         1,118         4,055           Current portion of fixed payment arrangements         1,12         2,128           Current portion of contingent consideration         1,13         4,055           Current portion of contingent consideration         1,13         4,055           Long-term operating lease liability, net of current portion         2,158         2,258           Long-term operating lease liability, net of current portion         2,158         2,258           Long-term porting lease liability, net of current portion         3,18         4,055           Long-term fixed payment arrangements, net of current portion         3,12         1,177           Long-term Experimed Stock par	Other long-term assets		465	465	
Labilities           Current liabilities         \$ 9,383         \$ 19,255           Accounts payable and other         \$ 6,380         \$ 1,295           Accrued liabilities         54,380         \$ 1,295           Accrued compensation         4762         \$ 5,939           Short-term line of credit         4,520         7,934           Current portion of debt         16,508         16,668           Current portion of payment arrangements         1,02         3,121           Current portion of CVR liabilities         1         2,13           Current portion of contingent consideration         4,138         4,055           Total current ignore of current portion         1,14         1,80           Long-term portion of contingent consideration         1,5         3,221         3,134           Current portion of contingent consideration         1,5         3,05         3,05           Total current portion of contingent consideration of current portion         1,5         3,05         3,05           Long-term fide payment arrangements, set of current portion         5,632         4,05         4,05           Long-term (bet), ret of current portion         5,632         6,234         6,324         6,324         6,324         6,324         6,324	Total long-term assets		138,691	160,434	
Accounts payable and other         \$ 9,383         \$ 19,285           Accounts payable and other         54,380         51,285           Accounts payable and other         54,380         51,285           Account dempensation         4,762         5,938           Account dempensation         4,762         5,938           Short-term line of credit         64,520         7,938           Current portion of debt         16,508         16,668           Current portion of fixed payment arrangements         1,084         940           Current portion of CVRI liabilities         1         1         218           Current portion of contingent consideration         9,797         109,438           Long-term portion of contingent consideration         97,997         109,438           Long-term debt, net of current portion         97,997         109,438           Long-term depending lease liability, net of current portion         97,997         109,438           Long-term Experiment parangements, net of current portion         1,347         1,107           Long-term Experiment contingent consideration, net of current portion         1,347         1,117           Cotal liabilities         1,347         1,247         1,247           Chall slabilities         1,248         1,248<	Total assets	\$	227,729	\$ 265,668	
Accounts payable and other         \$ 9,383         \$ 19,255           Accrued liabilities         54,380         51,295           Accrued compensation         4,762         5,939           Short-term line of credit         4,520         7,934           Current portion of debt         16,508         16,508           Current portion of Swepament arrangements         3,221         3,134           Current portion of CVR liabilities         9,799         10,948           Current portion of condingent consideration         4,13         4,055           Total current liabilities         97,999         109,438           Long-term flee, the of current portion         9,799         109,438           Long-term flee, the of current portion         2,758         2,624           Long-term flee, the of current portion         5,485         6,324           Long-term flee, the of current portion         5,485         6,324           Long-term flee, the of current portion         8,169         8,002           Long-term flee, the of current portion	Liabilities				
Accrued liabilities         54,380         51,295           Accrued compensation         4,762         5,939           Accrued compensation         4,762         7,934           Short-term line of credit         4,500         7,934           Current portion of debt         16,508         16,608           Current portion of operating lease liabilities         1,084         940           Current portion of fixed payment arrangements         3,221         3,134           Current portion of CvR liabilities         1         218           Current portion of condigeration         4,138         4,055           Total current liabilities         1         1,804         9,055           Total current portion of cornigeration for consideration         1,944         1,805         1,804         1,805           Long-term fixed payment arrangements         2,758         2,624         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,805         6,224         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804         1,804<	Current liabilities				
Accrued compensation         4,762         5,939           Short-term line of credit         4,520         7,934           Current portion of celd the current portion of operating lease liabilities         16,568         16,668           Current portion of operating lease liabilities         1,084         940           Current portion of CVR liabilities         3,221         3,134           Current portion of contingent consideration         4,138         4,055           Total current liabilities         97,997         109,438           Long-term debel, net of current portion         15         180           Long-term facel, net of current portion         2,758         2,624           Long-term fore payment arrangements, net of current portion         3,275         2,624           Long-term fore payment arrangements, net of current portion         1,347         1,137           Long-term fore payment arrangements, net of current portion         3,169         3,002           Other long-term fore payment arrangements, net of current portion         3,169         3,002           Other long-term fore payment arrangements, net of current portion         3,169         3,002           Other long-term fore payment arrangements, net of current portion         3,169         3,002           Total liabilities         3,169         3,002	Accounts payable and other	\$	9,383	\$ 19,255	
Short-term line of credit         4,520         7,934           Current portion of debt         16,508         16,668           Current portion of operating lease liabilities         1,048         940           Current portion of fixed payment arrangements         3,221         3,134           Current portion of CVR liabilities         1         218           Current portion of CVR liabilities         97,997         109,438           Current portion of contingent consideration         97,997         109,438           Long-term portion of experim portion         154         180           Long-term debt, net of current portion         154         180           Long-term dept, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term fixed payment arrangements, net of current portion         1,347         1,177           Long-term Contingent consideration, net of current portion         8,169         8,024           Long-term contingent consideration, net of current portion         8,169         8,002           Total liabilities         2,115,229         128,100           Total liabilities         2,100         2,100         2,100         2,100           Current portion of	Accrued liabilities		54,380	51,295	
Current portion of debt         16,508         16,608           Current portion of operating lease liabilities         1,084         940           Current portion of CVR liabilities         3,221         3,134           Current portion of cotniquent consideration         4,138         4,055           Current portion of cotniquent consideration         97,997         109,438           Long-term debt, net of current portion         154         180           Long-term debt, net of current portion         154         180           Long-term debt, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         8,169         8,022           Long-term contingent consideration, net of current portion         8,169         8,002           Other long-term liabilities         316         3,55           Total liabilities         116,229         128,100           Commitments and contingencies         116,229         128,100           Stockholders' equity         2         2           Preferred Stock, par value \$,0001; 20,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021         3         3	Accrued compensation		4,762	5,939	
Current portion of operating lease liabilities         1,084         940           Current portion of Kxed payment arrangements         3,221         3,134           Current portion of CVR liabilities         1         28           Current portion of contingent consideration         4,138         4,055           Total current liabilities         97,997         109,438           Long-term debri, net of current portion         1,54         18           Long-term operating lease liability, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term (XR liabilities, net of current portion         1,147         1,177           Long-term Contingent consideration, net of current portion         3,169         8,052           Other long-term liabilities         319         355           Total liabilities         319         355           Total liabilities         116,229         128,100           Comments and contingencies         116,229         128,100           Comments and contingencies         3         3         3           Stockholders' equity         7         -         -           Preferred Stock, par value \$,0001; 200,000,000 shares authorized; shares issued and outstandi	Short-term line of credit				
Current portion of fixed payment arrangements         3,221         3,134           Current portion of CVR liabilities         1         218           Current portion of contingent consideration         4,138         4,055           Current portion of contingent consideration         97,997         109,438           Long-term debt, net of current portion         154         180           Long-term operating lease liability, net of current portion         2,758         2,624           Long-term CVR liabilities, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         8,169         8,002           Other long-term insiabilities         319         355           Total liabilities         319         355           Commitments and contingencies         316         28           Stockholders' equity           Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         31,364         31,564           Additional paid-in capital         31,647         315,864         31,586           Accumulated deficit         (206,150)         (178,299)         101,78,299	Current portion of debt			.,	
Current portion of CVR liabilities         1         218           Current portion of contingent consideration         4,138         4,055           Total current liabilities         97,997         109,438           Long-term debt, net of current portion         154         180           Long-term poerating lease liability, net of current portion         2,758         2,624           Long-term CVR liabilities, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         8,169         8,002           Other long-term CVR liabilities, net of current portion         8,169         8,002           Other long-term CVR liabilities         319         355           Total liabilities         319         355           Total liabilities         524         424           Comments and contingencies         319         355           Stockholders' equity         525         524           Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         3         3         3           2021         40ditional paid-in capital         41,547         315,864         3         3         3           Accumulated deficit         (206,159)         (178,299)	Current portion of operating lease liabilities				
Current portion of contingent consideration         4,138         4,055           Total current liabilities         97,997         109,438           Long-term debt, net of current portion         15,40         180           Long-term operating lease liability, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         8,169         8,002           Long-term contingent consideration, net of current portion         319         355           Total labilities         319         355           Total labilities         116,299         128,100           Comments and contingenet consideration, net of current portion         201         202           Comments and contingenetics         319         355           Total labilities         5,405         116,299         128,100           Comments and contingenetics         310         2021         2021           Comments Stock, par value \$.0001; 200,000,000 shares authorized; shares issued or outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021         3         3         3           Additional paid-in capital         317,647         315,864         315,864         30,106,407	Current portion of fixed payment arrangements				
Total current liabilities         97,997         109,438           Long-term debt, net of current portion         154         180           Long-term debt, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         1,347         1,177           Long-term consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies           Stockholders' equity           Preferred Stock, par value 5,0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         5         -	Current portion of CVR liabilities				
Long-term debt, net of current portion         154         180           Long-term operating lease liability, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         1,1347         1,177           Long-term contingent consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contringencies         5         5           Stockholders' equity         5         5           Preferred Stock, par value \$,0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         5         5           Common Stock, par value \$,0001; 50,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021         3         3           Additional paid-in capital         317,647         315,864           Accumulated deficit         (206,150)         (178,299)           Total stockholders' equity         111,500         137,568	Current portion of contingent consideration				
Long-term operating lease liability, net of current portion         2,758         2,624           Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         1,347         1,174           Long-term Contingent consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies         5         -           Stockholders' equity         -         -         -           Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         3         3           2021         317,647         317,647         315,864           Additional paid-in capital         317,647         315,864           Accumulated deficit         (206,150)         (178,299)           Total stockholders' equity         111,500         137,568					
Long-term fixed payment arrangements, net of current portion         5,485         6,324           Long-term CVR liabilities, net of current portion         1,347         1,177           Long-term consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies         5         -           Stockholders' equity         -         -         -         -           Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         -	Long-term debt, net of current portion				
Long-term CVR liabilities, net of current portion         1,347         1,177           Long-term contingent consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies         ************************************					
Long-term contingent consideration, net of current portion         8,169         8,002           Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies         ****         ****           Stockholders' equity         ****         ****         ****           Preferred Stock, par value \$,0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         ***         ***         ***           Common Stock, par value \$,0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021         3         3         3           Additional paid-in capital         \$317,647         315,664         315,664         315,664         315,664         317,647         315,664         316,064         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647         315,664         317,647 <td></td> <td></td> <td></td> <td></td>					
Other long-term liabilities         319         355           Total liabilities         116,229         128,100           Commitments and contingencies         128,100         128,100           Stockholders' equity           Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         21         2         2         2         2         2         2         2         3         3         3         3         3         3         3         317,647         315,646         317,647         315,864         317,647         315,864         3         <					
Total liabilities         116,229         128,100           Commitments and contingencies         116,229         128,100           Stockholders' equity           Preferred Stock, par value \$,0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021         -				.,	
Commitments and contingencies Stockholders' equity Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021 Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021 Additional paid-in capital Accumulated deficit Control Stock par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021 3 3 3. Additional paid-in capital Accumulated deficit Control Stock par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021					
Stockholders' equity  Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021  Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021  Additional paid-in capital  Accumulated deficit  Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021 and			116,229	 128,100	
Preferred Stock, par value \$.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2021 and June 30, 2021  Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021  3 3 3  Additional paid-in capital  Accumulated deficit (206.150) (178.299)  Total stockholders' equity					
Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30, 2021         3         3           Additional paid-in capital         317,647         315,864           Accumulated deficit         (206,150)         (178,299)           Total stockholders' equity         111,500         137,568			_	_	
Additional paid-in capital     317,647     315,864       Accumulated deficit     (206,150)     (178,299)       Total stockholders' equity     111,500     137,568	Common Stock, par value \$.0001; 200,000,000 shares authorized; shares issued and outstanding 27,771,912 and 27,490,412, respectively, as of September 30, 2021 and June 30,		2	3	
Accumulated deficit         (206,150 )         (178,299 )           Total stockholders' equity         111,500         137,568					
Total stockholders' equity 111,500 137,568					
	Total liabilities and stockholders' equity	\$	227,729	\$ 265,668	

#### **Contact for Media and Investors:**

Sarah McCabe Stern Investor Relations, Inc. Sarah.mccabe@sternir.com

**SOURCE:** Aytu BioPharma, Inc.

View source version on accesswire.com:

https://www.accesswire.com/672723/Aytu-BioPharma-Reports-First-Quarter-2022-Financial-Results